KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $495.7 million.

  • AbCellera Biologics' Cash & Equivalents fell 22.93% to $495.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $495.7 million, marking a year-over-year decrease of 22.93%. This contributed to the annual value of $625.6 million for FY2024, which is 17.75% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Cash & Equivalents is $495.7 million, which was down 10.38% from $553.1 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Cash & Equivalents ranged from a high of $1.0 billion in Q2 2022 and a low of $495.7 million during Q3 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $670.4 million (2024), whereas its average is $675.4 million.
  • As far as peak fluctuations go, AbCellera Biologics' Cash & Equivalents surged by 67.71% in 2022, and later fell by 22.93% in 2025.
  • Over the past 5 years, AbCellera Biologics' Cash & Equivalents (Quarterly) stood at $723.0 million in 2021, then rose by 22.62% to $886.5 million in 2022, then decreased by 14.20% to $760.6 million in 2023, then dropped by 17.75% to $625.6 million in 2024, then fell by 22.93% to $495.7 million in 2025.
  • Its Cash & Equivalents stands at $495.7 million for Q3 2025, versus $553.1 million for Q2 2025 and $605.3 million for Q1 2025.